Clonidine - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for clonidine and what is the scope of freedom to operate?
Clonidine
is the generic ingredient in eleven branded drugs marketed by Tris Pharma Inc, Lavipharm, Actavis Labs Ut Inc, Difgen Pharms, Dr Reddys Labs Sa, Mylan Technologies, Athena, Am Regent, Fresenius Kabi Usa, Hikma Farmaceutica, Xgen Pharms, Zydus Pharms, Mylan Institutional, Actavis Elizabeth, Ajanta Pharma Ltd, Amneal Pharms Ny, Chartwell Rx, Endo Operations, Jubilant Generics, Novast Labs, Somerset Theraps Llc, Xiamen Lp Pharm Co, Concordia Pharms Inc, Boehringer Ingelheim, Alembic Pharms Ltd, Am Therap, Aurobindo Pharma Ltd, Chartwell Molecules, Duramed Pharms Barr, Impax Labs, Interpharm, Par Pharm, Prinston Inc, Rising, Sun Pharm Inds Inc, Teva, Trupharma, Unichem, Warner Chilcott, Watson Labs, and Yung Shin Pharm, and is included in sixty-five NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Clonidine has twenty-one patent family members in fourteen countries.
There are twenty-two drug master file entries for clonidine. Eight suppliers are listed for this compound.
Summary for clonidine
International Patents: | 21 |
US Patents: | 4 |
Tradenames: | 11 |
Applicants: | 41 |
NDAs: | 65 |
Drug Master File Entries: | 22 |
Finished Product Suppliers / Packagers: | 8 |
Raw Ingredient (Bulk) Api Vendors: | 58 |
Clinical Trials: | 378 |
Patent Applications: | 6,340 |
Drug Prices: | Drug price trends for clonidine |
Drug Sales Revenues: | Drug sales revenues for clonidine |
What excipients (inactive ingredients) are in clonidine? | clonidine excipients list |
DailyMed Link: | clonidine at DailyMed |
Recent Clinical Trials for clonidine
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Universidad Simón Bolívar | Phase 3 |
National Cancer Institute, Egypt | N/A |
Sollis Therapeutics, Inc. | Phase 3 |
Pharmacology for clonidine
Drug Class | Central alpha-2 Adrenergic Agonist |
Mechanism of Action | Adrenergic alpha2-Agonists |
Medical Subject Heading (MeSH) Categories for clonidine
Anatomical Therapeutic Chemical (ATC) Classes for clonidine
US Patents and Regulatory Information for clonidine
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Difgen Pharms | CLONIDINE | clonidine | SYSTEM;TRANSDERMAL | 076157-003 | Aug 18, 2009 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Impax Labs | CLONIDINE HYDROCHLORIDE | clonidine hydrochloride | TABLET;ORAL | 078099-001 | Aug 27, 2009 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Endo Operations | CLONIDINE HYDROCHLORIDE | clonidine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 202983-001 | Apr 2, 2014 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Rising | CLONIDINE HYDROCHLORIDE | clonidine hydrochloride | TABLET;ORAL | 070317-001 | Jun 9, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Dr Reddys Labs Sa | CLONIDINE HYDROCHLORIDE | clonidine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 210680-001 | Apr 30, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Concordia Pharms Inc | KAPVAY | clonidine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022331-004 | Sep 28, 2010 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for clonidine
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lavipharm | CATAPRES-TTS-3 | clonidine | SYSTEM;TRANSDERMAL | 018891-003 | Oct 10, 1984 | ⤷ Sign Up | ⤷ Sign Up |
Lavipharm | CATAPRES-TTS-3 | clonidine | SYSTEM;TRANSDERMAL | 018891-003 | Oct 10, 1984 | ⤷ Sign Up | ⤷ Sign Up |
Lavipharm | CATAPRES-TTS-1 | clonidine | SYSTEM;TRANSDERMAL | 018891-001 | Oct 10, 1984 | ⤷ Sign Up | ⤷ Sign Up |
Lavipharm | CATAPRES-TTS-1 | clonidine | SYSTEM;TRANSDERMAL | 018891-001 | Oct 10, 1984 | ⤷ Sign Up | ⤷ Sign Up |
Lavipharm | CATAPRES-TTS-1 | clonidine | SYSTEM;TRANSDERMAL | 018891-001 | Oct 10, 1984 | ⤷ Sign Up | ⤷ Sign Up |
Lavipharm | CATAPRES-TTS-2 | clonidine | SYSTEM;TRANSDERMAL | 018891-002 | Oct 10, 1984 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for clonidine
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 101400343 | Modified release formulations containing drug-ion exchange resin complexes | ⤷ Sign Up |
Australia | 2007227569 | Modified release formulations containing drug-ion exchange resin complexes | ⤷ Sign Up |
Spain | 2378573 | ⤷ Sign Up | |
Japan | 2009530298 | ⤷ Sign Up | |
Russian Federation | 2008140944 | КОМПОЗИЦИИ С МОДИФИЦИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ КОМПЛЕКСЫ ЛЕКАРСТВЕННОЕ ВЕЩЕСТВО-ИОНООБМЕННАЯ СМОЛА | ⤷ Sign Up |
Taiwan | 200812649 | Modified release formulations containing drug-ion exchange resin complexes | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.